cabozantinib

Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.

Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.

Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).

Cabozantinib-D4 (Standard) is a reference standard of Cabozantinib-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Cabozantinib-d4 is the deuterated analog of Cabozantinib, an effective multi-receptor tyrosine kinase inhibitor. It targets VEGFR2, c-Met, Kit, Axl, and Flt3 with IC50 values of 0.035, 1.3, 4.6, 7, and 11.3 nM, respectively.

3-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid is a target protein ligand-linker conjugate combining a c-Met ligand with a PROTAC linker to recruit E3 ligase. It is applicable for synthesizing PROTACs, such as SJF-8240.

3-Fluoro-desmethyl-cabozantinib is a BCL6 ligand utilized in the synthesis of PROTACs, such as SJF-8240.

Cabozantinib impurity 8 is a type of Cabozantinib impurity.

Cabozantinib impurity 1 is an impurity of Cabozantinib.

Cabozantinib impurity 7 is a type of Cabozantinib impurity.

Cabozantinib-D6 is the deuterated form of Cabozantinib. As a potent multi-receptor tyrosine kinase inhibitor, Cabozantinib (T2586) targets VEGFR2, c-Met, Kit, Axl, and Flt3 with IC50 values of 0.035, 1.3, 4.6, 7, and 11.3 nM, respectively.

Cabozantinib-D4 is the deuterated analog of Cabozantinib (T2586), an effective multi-receptor tyrosine kinase inhibitor. It targets VEGFR2, c-Met, Kit, Axl, and Flt3 with IC50 values of 0.035, 1.3, 4.6, 7, and 11.3 nM, respectively.

Conteltinibtetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride form of Conteltinib. It acts as an inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. When used in combination with Cabozantinib, Conteltinib tetrahydrochloride exhibits a synergistic antitumor effect.